Bisi, J. E., Sorrentino, J. A., Jordan, J. L., Darr, D. D., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2017). Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget.

Bisi, John E., Jessica A. Sorrentino, Jamie L. Jordan, David D. Darr, Patrick J. Roberts, Francis X. Tavares, and Jay C. Strum. "Preclinical Development of G1T38: A Novel, Potent and Selective Inhibitor of Cyclin Dependent Kinases 4/6 for Use As an Oral Antineoplastic in Patients With CDK4/6 Sensitive Tumors." Oncotarget 2017.

Bisi, John E., et al. "Preclinical Development of G1T38: A Novel, Potent and Selective Inhibitor of Cyclin Dependent Kinases 4/6 for Use As an Oral Antineoplastic in Patients With CDK4/6 Sensitive Tumors." Oncotarget 2017.